These data indicate that PGE2 antagonism may be superior to NFκB blockade in modulating the bladder cancer microenvironment, due to its unique ability to enhance both the overall potency and specificity of action of BCG. This evidence concerns the gene NFKB1 and urinary bladder carcinoma.